Last reviewed · How we verify
GDC-0084
At a glance
| Generic name | GDC-0084 |
|---|---|
| Sponsor | Genentech, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 5G-PEARL: Paxalisib in Malignant Brain Tumours (PHASE1, PHASE2)
- GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases (PHASE2)
- Combination Therapy for the Treatment of Diffuse Midline Gliomas (PHASE2)
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (PHASE2, PHASE3)
- Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL (PHASE2)
- GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases (PHASE1)
- Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma (PHASE2)
- Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GDC-0084 CI brief — competitive landscape report
- GDC-0084 updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI